Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 330 + Pembrolizumab in R/R AML
NCT04478695Phase 1Terminated
- Sponsor
- Amgen
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of eluvixtamab in acute myeloid leukemia (AML) (2 cohorts), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicities at 28 days, Treatment-emergent Adverse Events and 1 more. Started Sep 2020; status: terminated.
02
Drugs
eluvixtamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04478695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478695.